Investors in Physicians Realty Trust (Symbol: DOC) saw new options become available this week, for the March 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DOC options chain for the new March 15th contracts and identified the following put contract of particular interest.
The put contract at the $12.50 strike price has a current bid of 30 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $12.50, but will also collect the premium, putting the cost basis of the shares at $12.20 (before broker commissions). To an investor already interested in purchasing shares of DOC, that could represent an attractive alternative to paying $12.89/share today.
Because the $12.50 strike represents an approximate 3% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 63%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 2.40% return on the cash commitment, or 15.65% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for Physicians Realty Trust, and highlighting in green where the $12.50 strike is located relative to that history:
The implied volatility in the put contract example above is 31%.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 251 trading day closing values as well as today's price of $12.89) to be 27%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Also see: SAR Split History
RAND Dividend Growth Rate
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.